SCHEMBL5876068

SCHEMBL5876068

Cc1ccc(S(=O)(=O)n2nc(C(=O)O)c3c2CC(c2ccncn2)(c2ccncn2)C=C3)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
KDM4E B2RXH2 2/20 0.32
KMT2A Q03164 5/20 0.32
MEN1 O00255 3/20 0.32
MAPT P10636 3/20 0.32
ALDH1A1 P00352 3/20 0.31
POLB P06746 2/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
GAA P10253 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA9 Q16790 1/20 0.31
CYP2C19 P33261 1/20 0.30
F2 P00734 1/20 0.30
CTSB P07858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876688 0.94 CYP2C19 (0.36) NR1H2NR1H3KDM4EKMT2AMEN1
SCHEMBL5875928 0.89 ALDH1A1 (0.39) NR1H2NR1H3KDM4EALDH1A1POLB
SCHEMBL5877203 0.87 KMT2A (0.38) NR1H2NR1H3KDM4EKMT2AMEN1
SCHEMBL5876034 0.86 NR1H2 (0.36) NR1H2NR1H3KDM4EKMT2AMEN1
SCHEMBL5877004 0.84 ALDH1A1 (0.37) NR1H2NR1H3KDM4EALDH1A1POLB
SCHEMBL5876231 0.84 CYP2C19 (0.39) NR1H2NR1H3KDM4EKMT2AALDH1A1
SCHEMBL5876186 0.83 CYP2C19 (0.42) NR1H2NR1H3KDM4EKMT2AMEN1
SCHEMBL5877005 0.83 NR1H2 (0.33) NR1H2NR1H3KDM4EKMT2AMEN1
SCHEMBL5877423 0.82 ALDH1A1 (0.36) NR1H2NR1H3MAPTALDH1A1LMNA
SCHEMBL5876342 0.82 CCR6 (0.35) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT NR1H2 556/4885NR1H3 456/4885KDM4E 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.